Drug therapy for prevention or treatment of glaucoma

Combining (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine with prostaglandins like latanoprost provides a robust and sustained intraocular pressure-lowering effect, addressing the limitations of existing treatments for glaucoma and ocular hypertension.

JP2024160001AInactive Publication Date: 2024-11-08KOWA CO LTD
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2024151118
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-02-04
Filing Date
2024-09-03
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing treatments for glaucoma and ocular hypertension, including combinations of drugs, do not provide a strong and prolonged intraocular pressure-lowering effect, particularly in normal-tension glaucoma.

Method used

Combining (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or its salts or solvates with prostaglandins, such as latanoprost, to enhance the intraocular pressure-lowering effect and duration.

Benefits of technology

The combination achieves a strong and prolonged reduction in intraocular pressure, effectively treating glaucoma and ocular hypertension, including normal-tension glaucoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160001000001
    Figure 2024160001000001
Patent Text Reader

Abstract

To provide a drug therapy for preventing glaucoma or preventing or treating ocular hypertension, which has a strong effect of lowering intraocular pressure with the effect's duration extended.SOLUTION: Provided is a combination of (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof or a solvate thereof with prostaglandins for the prevention or treatment of glaucoma.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmacotherapy for the prevention or treatment of glaucoma or ocular hypertension. [Background technology]

[0002] Glaucoma is a condition in which intraocular pressure increases due to various causes, causing the optic nerve to become damaged and shrink, resulting in visual field abnormalities. However, it is a disease that leads to a decline in vision. Once the optic nerve has atrophied, it cannot recover, so green If cataracts are left untreated, they can lead to blindness, and even if treatment is successful, the condition will remain the same, with no hope of recovery. It is a difficult-to-treat disease. Although it does not cause visual field abnormalities, it may develop into glaucoma over the long term. Ocular hypertension, which is highly susceptible to eye strain, also poses a similar risk.

[0003] Glaucoma is divided into three types: congenital glaucoma, secondary glaucoma, and primary glaucoma. This type of glaucoma occurs when the angle of the eye is congenitally underdeveloped, preventing the drainage of aqueous humor. Secondary glaucoma is glaucoma caused by obvious causes such as inflammation or injury, and is not caused by uveitis or eye injury. In addition to eye-related causes such as bleeding due to diabetes, steroid hormones used to treat other diseases, Primary glaucoma is a general term for glaucoma whose causes are unclear. It is most common in middle-aged and elderly people and is the most common type of glaucoma. Glaucoma can be further divided into two types: open-angle glaucoma and closed-angle glaucoma, depending on how the aqueous humor flow is blocked. There are also many patients who develop normal tension glaucoma, which is not accompanied by an increase in intraocular pressure. Regardless, the primary goal of glaucoma treatment is to reduce intraocular pressure.

[0004] Treatment for glaucoma is when intraocular pressure cannot be controlled with medication or when patients with angle-closure glaucoma develop acute glaucoma. In the event of an attack, laser therapy (laser trabeculoplasty) or surgical treatment (fibroblast replacement) may be used. Treatments include trabeculectomy and trabeculotomy, but drug therapy is used as the first choice. Drug therapy for glaucoma includes sympathomimetics (non-selective stimulants such as epinephrine, apraxon, etc.) α2 agonists such as nidin), sympatholytics (timolol, befunolol, carteolol) , Nipradilol, Betaxol, Levobunolol, Metipranolol, etc. beta-blockers, alpha-1 blockers such as bunazosin hydrochloride), parasympathomimetics (pilocarpine, etc.), Carbonic anhydrase inhibitors (acetazolamide, etc.), prostaglandins (isopropyl Roston, latanoprost, travoprost, bimatoprost, tafluprost, etc.) It is used.

[0005] Among these drugs, prostaglandins inhibit the outflow of aqueous humor from the uveoscleral outflow pathway. It is a type of drug that promotes the reduction of intraocular pressure and is widely used clinically (Non-Patent Document 1). .

[0006] On the other hand, Rho kinase inhibitors are considered to be candidates for glaucoma treatment based on a new mechanism of action. Rho kinase inhibitors inhibit the accumulation of fibrous trabecular outflow pathways in the tufts of the fibrous trabecular meshwork. It reduces intraocular pressure by promoting aqueous outflow (Non-Patent Document 2), and this effect is further enhanced by the trabecular meshwork cells. It has been suggested that this is due to changes in the cytoskeleton in the cells (Non-Patent Documents 2 and 3). .

[0007] Furthermore, in the case of glaucoma or ocular hypertension, in order to enhance the intraocular pressure lowering effect, For example, prostaglandins and In combination with a neuropathic drug (Patent Document 3), or with a drug that has an intraocular pressure reducing effect, A method for treating glaucoma by administering a combination of these drugs to the eye (Patent Document 4) has also been reported. Rho kinase inhibitors also have been shown to be effective in combination with prostaglandins. There have also been reports of therapeutic agents for glaucoma (Patent Documents 5 to 7).

[0008] However, the above-mentioned known therapeutic agents and methods for glaucoma and ocular hypertension are However, it is still difficult to say that the strength and duration of the blood pressure-lowering effect are satisfactory. In normal tension glaucoma, lowering normal intraocular pressure is more difficult than lowering elevated intraocular pressure. However, the above existing drugs and their combinations have limitations in treating normal tension glaucoma. However, there is a demand in the medical field for further strengthening the intraocular pressure reducing effect. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] International Publication WO00 / 09162 Brochure [Patent Document 2] Japanese Patent Application Publication No. 11-349482 [Patent Document 3] Patent No. 2726672 [Patent Document 4] International Publication WO02 / 38158 Brochure [Patent Document 5] JP 2004-107335 A [Patent Document 6] International Publication WO07 / 026664 Brochure [Patent Document 7] International Publication WO08 / 105058 Brochure [Non-patent literature]

[0010] [Non-Patent Document 1] New Ophthalmology, 15(4), 475-480(1998) [Non-Patent Document 2] IOVS,42(1),137-144(2001) [Non-Patent Document 3] IOVS,42(5),1029-1037(2001) Summary of the Invention [Problem to be solved by the invention]

[0011] The present invention relates to a method for treating glaucoma or hyperostosis, which has a strong intraocular pressure reducing effect and a prolonged duration of the effect. The present invention relates to providing a pharmacotherapy for the prevention or treatment of hypertension. [Means for solving the problem]

[0012] As a result of intensive research aimed at solving the above problems, the present inventors have discovered that (S)-(-)-1-( 4-Fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt or solvate thereof may be administered in combination with a prostaglandin. It was discovered that this exerts a strong intraocular pressure lowering effect and extends its duration. Ta.

[0013] That is, the present invention relates to the following inventions. 1) (S)-(-)-1-(4-fluoro-5-isoquinoline) for the prevention or treatment of glaucoma (Norinsulfonyl)-2-methyl-1,4-homopiperazine or its salts or Combination of solvates with prostaglandins. 2) The combination of 1) above, wherein the prostaglandin is latanoprost. 3) A combination of 1) or 2) above which is a compounding agent. 4) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl A drug containing 1,4-dihydro-1,4-homopiperazine and a drug containing prostaglandins A combination of 1) or 2) above which is a kit comprising drugs. 5) (S)-(-)-1-(4-fluoro-5-isopropyl)phenylacetamide for the prevention or treatment of ocular hypertension Quinolinesulfonyl)-2-methyl-1,4-homopiperazine or its salt or A combination of a solvate of the formula (I) with a prostaglandin. 6) The combination of 5) above, wherein the prostaglandin is latanoprost. 7) A combination of the above 5) or 6) which is a compounding agent. 8) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl A drug containing 1,4-dihydro-1,4-homopiperazine and a drug containing prostaglandins The combination of 5) or 6) above, which is a kit comprising a drug. 9) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl 1,4-Homopiperazine or its salt or solvate and prostaglandin A method for preventing or treating glaucoma, comprising administering to a patient in combination with one or more of the above-mentioned compounds. 10) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl 1,4-Homopiperazine or its salts or solvates and prostaglandins A method for preventing or treating ocular hypertension, comprising administering to the patient in combination with a compound similar to that described above. Effect of the Invention

[0014] According to the present invention, a compound having a potent intraocular pressure lowering effect and a prolonged duration of the effect is provided for treating glaucoma or other glaucoma. may provide a means of preventing or treating ocular hypertension. [Brief description of the drawings]

[0015] [Figure 1] Graph showing the change in intraocular pressure over time in each administration group. Intraocular pressure is shown as the change from the initial intraocular pressure (mean ± standard error). □: Group administered with Latanoprost alone, ○: Group administered with (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine (compound 1) alone, ●: Group administered with Latanoprost and (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine (compound 1) in combination, statistical analysis: *p<0.05 vs. compound 1 group, #p<0.05, ##p<0.01 vs. Latanoprost group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl) used in the present invention -2-Methyl-1,4-homopiperazine has substance P antagonistic activity and leukotriene D The compound has an antagonistic effect against Rho kinase and an inhibitory effect against Rho kinase. It can be produced by the method described in International Patent Publication No. 99 / 20620. .

[0017] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- Examples of salts of 1,4-homopiperazine include hydrochloric acid, sulfuric acid, nitric acid, hydrofluoric acid, and hydrobromic acid. Salts of inorganic acids such as benzoic acid, acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, sulfonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid Examples of the salts include salts with organic acids such as naphthalenesulfonic acid and camphorsulfonic acid, and in particular salts with hydrochloric acid. Salt is preferred.

[0018] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine or its salts may be used in the form of unsolvated as well as hydrated or solvated forms. Hydrates are preferred, but all crystalline forms and hydrates are contemplated for the purposes of the present invention. This includes hydrates and solvates.

[0019] On the other hand, prostaglandins have an intraocular pressure reducing effect and are useful in the treatment of glaucoma. Specific examples of prostaglandins having an intraocular pressure reducing effect are described in Japanese Patent Application Laid-Open No. 1984. Prostaglandins (especially prostaglandin F2α) disclosed in US Pat. No. 5,399,433 and US Pat. No. 5,399,433 are disclosed in US Pat. No. 5,399,433. (natural prostaglandin), latanoprost disclosed in Japanese Patent Publication No. 3-501025 prostaglandins such as stearic acid, isopropyl phosphate, etc., Prostaglandins such as rostone, bimatoprostol disclosed in Japanese Patent Publication No. 8-501310 Prostaglandins such as Rost, and traboprostaglandins disclosed in JP-A-10-182465 prostaglandins such as Rost, and taflup disclosed in JP-A-11-071344 Examples include prostaglandins such as rostanol, which are sold as glaucoma treatments. Latanoprost ((+)-Isopropyl(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydr oxy-5-phenylpentyl]cyclopentyl]-5-heptenoate), isopropyl unoprostone ((+)- isopropyl(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-eno ate), bimatoprost ((5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy- 5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide, travoprost (Iso propyl(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluorome thyl) phenoxy]but-1-enyl]cyclopentyl)hept-5-enoate) or tafluprost (1-Meth ylethyl(5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl]-3,5-dihyd [roxycyclopentyl]-5-heptenoate) is preferably used.

[0020] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine or its salt or solvate and prostaglandins When used in combination, as shown in the examples below, the effect is strong and long-lasting even at normal intraocular pressure. Therefore, these combinations are effective in preventing glaucoma and hypertension. These combinations are also useful as agents for preventing or treating glaucoma and ocular hypertension. The present invention can also be used in combination to produce a prophylactic or therapeutic agent for diseases. By administering the compound to a human (patient) in need of prevention or treatment of glaucoma or ocular hypertension, The glaucoma and ocular hypertension can be prevented or treated. Primary open-angle glaucoma, normal tension glaucoma, aqueous overproduction glaucoma, ocular hypertension, acute angle closure Glaucoma, chronic angle-closure glaucoma, plateau iris syndrome, mixed glaucoma Glaucoma, steroid-induced glaucoma, capsular glaucoma, pigmentary glaucoma, amyloid glaucoma, neovascularization Glaucoma is a condition that affects the eyes and eyesight. This refers to a condition in which abnormally high intraocular pressure is observed even though no clear lesions are found in the optic nerve. This includes many ocular hypertensive conditions, such as the later manifestations of ocular hypertension.

[0021] The present invention relates to a compound for preventing or treating glaucoma or ocular hypertension, -Fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or The combination of the steroids or their salts or solvates with prostaglandins is not available as a combination drug. The effective amounts of each ingredient may be formulated in a single dosage form at an appropriate mixing ratio, or Each drug may be formulated in a single formulation containing an effective amount of each drug and used simultaneously or separately at intervals. The kit may be a kit that can be used for the purpose.

[0022] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine or its salt or solvate and prostaglandins When the above are separately formulated, the respective formulations can be prepared according to known methods. For example, (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl Preparations of ethyl-1,4-homopiperazine or its salts or solvates thereof are not permitted in accordance with the above-mentioned Please refer to the formulation examples described in the International Patent Publications (WO00 / 09162, WO97 / 23222). The prostaglandin formulations can be prepared as described in the above-mentioned Japanese Patent Publication. Patent publications or Japanese published patent publications (JP Patent Publication No. 59-1418, JP Patent Publication No. 3-501025, Hei 2-108, Special Publication Hei 8-501310, Unexamined Publication Hei 10-182465, Unexamined Publication Hei 11-07 1344) and can be prepared by referring to the formulation examples described in the above. Latanoprost, isopropyl unoprostone, bimatoprost, trametinib, For boprost, tafluprost, etc., commercially available preparations can also be used.

[0023] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine or its salt or solvate and prostaglandins When preparing a preparation containing the above, it can be prepared according to a known method. For example, The eye solution is prepared by using an isotonic agent, a buffer, a surfactant, a preservative, etc. as necessary. The pH may be within the range acceptable for ophthalmic preparations, and is preferably in the range of pH 4 to 8. I wish.

[0024] The above preparations are preferably used as ophthalmic preparations, particularly as eye drops. Such eye drops are preferably water-soluble. The eye drops may be aqueous eye drops, non-aqueous eye drops, suspension eye drops, emulsion eye drops, eye ointments, etc. Such a formulation may be prepared as a composition suitable for the administration form, and may be optionally combined with a pharma- ceutically acceptable carrier. , for example, isotonicity agents, chelating agents, stabilizers, pH regulators, preservatives, antioxidants, solubilizing agents The composition can be prepared by mixing the composition with a thickening agent, a viscosity enhancer, etc., and by a (formulation) method known to those skilled in the art.

[0025] When preparing eye drops, for example, the desired components are dissolved in an aqueous solution such as sterilized purified water or physiological saline. or vegetable oils such as cottonseed oil, soybean oil, sesame oil, peanut oil, etc. The osmotic pressure can be adjusted to a predetermined level, and then sterilization such as filtration sterilization can be performed. When preparing an eye ointment, an ointment base can be contained in addition to the various ingredients described above. The ointment base is not particularly limited, but may be vaseline, liquid paraffin, polyethylene Oil-based bases such as hydroxypropyl cellulose; Emulsion bases in which the oil phase and the water phase are emulsified with a surfactant or the like; Hydroxypropyl cellulose Propyl methyl cellulose, carboxymethyl cellulose, polyethylene glycol, etc. Preferred examples of the water-soluble base include the following:

[0026] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- Prostaglandins with 1,4-homopiperazine or its salts or solvates When the combination is prepared as a kit for preventing or treating glaucoma or ocular hypertension, (S)-(-)-1-(4-fluoro-5-isoquinoline sulfonamide) formulated as above (2-methyl-1,4-homopiperazine or its salt or a solvate thereof The drug containing the prostaglandin and the drug containing the prostaglandin are packaged separately. Each drug product is then taken out of its respective package and used at the time of administration. In addition, each pharmaceutical formulation can be designed in a form suitable for single combined administration. You can also package it in.

[0027] (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine or its salt or solvate and prostaglandins When used in combination with the above for the prevention or treatment of glaucoma or ocular hypertension, the dosage is Although it varies depending on the patient's weight, age, sex, symptoms, dosage form and number of doses, it is usually For adults, (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)- 2-Methyl-1,4-homopiperazine or its salt or solvate thereof per day 0.025 to 10,000 μg, preferably 0.025 to 2,000 μg, more preferably 0 The range of 0.1 to 2000 μg per day is 0.1 to 10 The range of prostaglandins is 100 μg, preferably 1 to 300 μg. For example, latanoprost is administered at 1-5 μg per day, and isopropyl uracil is administered at 1-5 μg per day. In the case of Roston, 30 to 300 μg per day is usually used. In addition, (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl 1,4-Homopiperazine or its salt or solvate and prostaglandin When administered as a preparation containing the above-mentioned ingredients, the daily dosage is the amount of each ingredient listed above or A formulation may be prepared by appropriately selecting the blending ratio so that the amount is equal to or less than this range.

[0028] The number of administrations is not particularly limited, but it is preferable to administer the compound once or in several divided doses. In the case of liquid eye drops, one to several drops may be administered at a time. The individual preparations may be administered simultaneously or at intervals of 5 minutes to 24 hours. The present invention will be described in more detail below, but the present invention is not limited thereto. EXAMPLES

[0029] Example 1 (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1 To investigate the usefulness of combining 4-homopiperazine with prostaglandins The intraocular pressure-lowering effects of these drugs were compared when they were administered alone or in combination to experimental animals.

[0030] 1. Preparation of Test Compound Solutions A. (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl Preparation of 1,4-Homopiperazine Solution (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine monohydrochloride dihydrate was dissolved in physiological saline, and then sodium dihydrogen phosphate was added. Add sodium thorium and sodium hydroxide to neutralize the solution (pH 6.0) and adjust the concentration to the desired level. S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1, A 4-homopiperazine solution was prepared.

[0031] B. Preparation of Prostaglandins Commercially available latanoprost (Pfizer, 0.005% ophthalmic solution) was used as is.

[0032] 2. Test Method (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- We investigated the intraocular pressure-lowering effect of coadministration of 1,4-homopiperazine and latanoprost. As a control, (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl )-2-methyl-1,4-homopiperazine alone or latanoprost alone We also investigated the intraocular pressure-reducing effect of

[0033] A. Drugs and Animals Used in the Study (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine solution: 0.4% solution (amount to instilled: 20 μl) Latanoprost: 0.005% eye drops (amount instilled: 20 μl) Experimental animals: Cynomolgus monkeys (sex: male, 5 per group)

[0034] B. Methods of Administration and Measurement (1) Coadministration of both drugs 1) 4% oxybuprocaine hydrochloride eye drops (trade name: Benoxil 0.4% solution) were administered to the experimental animals. One drop was instilled into both eyes to administer local anesthesia (data only for the side where the eye was instilled). 2) The intraocular pressure was measured immediately before administration of the test compound solution and used as the initial intraocular pressure. 3) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl The 1,4-homopiperazine solution was instilled into one eye of the experimental animals, followed by latanoprost solution. was instilled into the same eye. 4) 0.4% oxybuproca hydrochloride 1, 2, 4 and 6 hours after instillation of both drugs A drop of the solution was instilled into each eye to anesthetize the subject, and intraocular pressure was then measured. (2) (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl Single administration of 1,4-homopiperazine (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- 1,4-Homopiperazine was administered alone at the same time as the combined administration test. .

[0035] (3) Latanoprost alone (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl The test solution containing 1,4-homopiperazine alone was replaced with latanoprost, and the others were the above-mentioned single The test was carried out in the same manner as in the administration test.

[0036] 3. Results and Discussion The results of the test are shown in Figure 1. The intraocular pressure is shown as the change from the initial intraocular pressure. Microsoft Excel 2000 SP-3 and paired t-test were used. As is clear from FIG. 1, (S)-(−)-1-(4-fluoro-5-isoquinoline The combination group of 2-methyl-1,4-homopiperazine and latanoprost was Single-treatment group, i.e., (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl) (p-Dimethylphenyl)-2-methyl-1,4-homopiperazine or latanoprost. The compound showed a remarkable intraocular pressure-reducing effect and showed improved durability of the effect. From the above, latanoprost and (S)-(-)-1-(4-fluoro-5-isoquinoline By combining it with sulfonyl-2-methyl-1,4-homopiperazine, it becomes more potent. It was found that this resulted in a rapid intraocular pressure reduction effect and an improved sustained effect. [Industrial Applicability]

[0037] The present invention relates to (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2- Methyl-1,4-homopiperazine or its salt or solvate and prostaglandin The combination of sedatives and sedatives has excellent intraocular pressure lowering effects and sustained effects, and is effective in treating glaucoma and Furthermore, it is useful as a medicament for the prevention or treatment of ocular hypertension.

Claims

1. (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- A combination of 1,4-homopiperazine or a salt thereof, or a solvate thereof and latanoprost. A glaucoma treatment agent comprising the above components.

2. The therapeutic agent for glaucoma according to claim 1, which is a combination drug.

3. (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- A drug comprising 1,4-homopiperazine and a drug comprising latanoprost. The therapeutic agent for glaucoma according to claim 1, which is a kit comprising:

4. (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- A combination of 1,4-homopiperazine or a salt thereof, or a solvate thereof and latanoprost. A therapeutic agent for ocular hypertension comprising the above-mentioned components.

5. The therapeutic agent for ocular hypertension according to claim 4, which is a combination drug.

6. (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl- A drug comprising 1,4-homopiperazine and a drug comprising latanoprost. The therapeutic agent for ocular hypertension according to claim 4, which is a kit comprising:

Citation Information

Patent Citations

  • Glaucoma-treating agent consisting of rho kinase inhibitor and prostaglandin

    JP2004107335A

  • Preventing or treating agent of glaucoma

    JP2006290827A

  • Composition for eye drop

    JP2007084474A

  • Preventive or remedy for glaucoma

    WO2006137368A1

  • Agent for prevention or treatment of glaucoma

    WO2007007737A1